Lisa Durkin

Lisa Durkin

Auto-generated profile, based on publicly available information

Lisa Durkin

Department of Pathology, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
DWDouglas W. Warden
Douglas W. Warden
SOSarah Do Ondrejka
Sarah Do Ondrejka
JLJeffrey Lin
Jeffrey Lin
LDLisa Bsc Durkin
Lisa Bsc Durkin
JBJuraj Bodo
Juraj Bodo
EHEric D. Hsi
Eric D. Hsi
BRAF V600E mutations are present in virtually all cases of hairy cell leukemia (HCL). We hypothesized that detection of phospho-ERK (pERK) in tissue sections may be a useful marker for diagnosis of HCL. pERK/CD20 double immunostaining was performed on 90 formalin-fixed bone marrow trephine samples affected with small B-cell lymphoproliferative disorders, including 28 cases of HCL. pERK staining was observed in all 28 cases of HCL and in 1 of 62 cases of non-HCL B-cell lymphoproliferative disorders. By allele-specific polymerase chain reaction, all 11 cases of HCL with available DNA were positive for BRAF V600E, as was the 1 pERK+ non-HCL case. The remaining 31 non-HCL cases tested were negative for BRAF V600E. The sensitivity and specificity of pERK for diagnosis of HCL was 100% and 98%, respectively. We conclude that the presence of pERK as detected by immunohistochemical staining is a useful surrogate marker for BRAF V600E in the diagnosis of HCL.


20 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
XGXiaorong Gu
Xiaorong Gu
RTRita Tohme
Rita Tohme
BTBenjamin Tomlinson
Benjamin Tomlinson
MHMetis Hasipek
Metis Hasipek
LDLisa Durkin
Lisa Durkin
YSYogen Saunthararajah
Yogen Saunthararajah
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid malignancies, require investigation and countermeasures. Both are nucleoside analog pro-drugs processed by pyrimidine metabolism into a nucleotide analog that depletes the key epigenetic regulator DNA methyltranseferase 1 (DNMT1). We report here that DNMT1 protein, although substantially depleted (~50%) in patients’ bone marrows at response, rebounded at relapse, and explaining this, we found pyrimidine metabolism gene expression shifts averse to the processing of each pro-drug. The same metabolic shifts observed clinically were rapidly recapitulated in leukemia cells exposed to the pro-drugs in vitro. Pyrimidine metabolism is a network that senses and preserves nucleotide balances: Decitabine, a deoxycytidine analog, and 5-azacytidine, a cytidine analog, caused acute and distinct nucleotide imbalances, by off-target inhibition of thymidylate synthase and ribonucleotide reductase respectively. Resulting expression changes in key pyrimidine metabolism enzymes peaked 72-96 hours later. Continuous pro-drug exposure stabilized metabolic shifts generated acutely, preventing DNMT1-depletion and permitting exponential leukemia out-growth as soon as day 40. Although dampening to activity of the pro-drug initially applied, adaptive metabolic responses primed for activity of the other. Hence, in xenotransplant models of chemorefractory AML, alternating decitabine with 5-azacytidine, timed to exploit compensating metabolic shifts, and addition of an inhibitor of a catabolic enzyme induced by decitabine/5-azacytidine, extended DNMT1-depletion and time-to-distress by several months versus either pro-drug alone. In sum, resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network; these responses can be anticipated and thus exploited. GRAPHICAL

2 November 2026 in Annals of Surgery
Verified
Journal Article
Closed access
SLSobia Laique
Sobia Laique
AHAwwab F. Hammad
Awwab F. Hammad
DADaniela Allende
Daniela Allende
HSHassan Siddiki
Hassan Siddiki
CWChase J Wehre
Chase J Wehre
AAAli Aminian
Ali Aminian
Objective: To evaluate histologic cirrhosis regression after metabolic bariatric surgery (MBS) in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Summary Background Data: Cirrhosis in MASH has traditionally been considered irreversible. Although MBS improves steatohepatitis and fibrosis in noncirrhotic MASH, its impact on established cirrhosis remains uncertain. Methods: This retrospective study included adults with biopsy-proven compensated MASH cirrhosis who underwent MBS at Cleveland Clinic from 2004 to 2024 and had paired baseline and follow-up liver biopsies. The primary outcome was regression from NASH Clinical Research Network (NASH CRN) stage 4 to stage 3 or lower. Fibrosis was also assessed using modified Ishak staging and the Beijing classification. Results: Thirty patients were included; 22 (73%) were female, median age was 54.2 years, and median baseline body mass index was 43.7 kg/m². The median (IQR) biopsy interval was 6.2 (2.0–9.2) years, median body weight reduction was 31.8 (21.4–40.4) kg, and median total weight loss was 23.9% (18.0%–30.5%). Cirrhosis regression occurred in 33% of patients using NASH CRN staging and in 40% using modified Ishak staging. Regressive fibrosis features were identified in 60% of patients using the Beijing classification. Significant improvements were also observed in steatosis, lobular inflammation, and hepatocyte ballooning. Conclusions: MBS was associated with histologic cirrhosis regression in a substantial proportion of patients with biopsy-proven compensated MASH cirrhosis. More detailed histologic frameworks identified additional fibrosis improvement and regressive remodeling, suggesting that compensated MASH cirrhosis may be reversible after sustained metabolic intervention.